Most US Adults With Hepatitis C Unaware of Infection, Study Finds
October 30th 2023Patients being unaware of their hepatitis C virus (HCV) infection is preventing the World Health Organization (WHO) from accomplishing its goal of eliminating HCV and hepatitis B virus as public threats by 2030.
Read More
Dr Saira Jan Details Current, Future Cost Savings From Oncology Therapeutics Home Infusion Program
October 30th 2023Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey, discussed cost savings that occurred so far from their collaborative pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health and also noted those they predict to occur as the program continues.
Watch
The European Medicines Agency (EMA) has accepted a marketing authorization application seeking the approval of mirvetuximab soravtansine-gynx for the treatment of patients with folate receptor alpha–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More
What We’re Reading: Pharmacy Staff Walkout; Male Parental Leave; FDA Reviewing SCD Therapy
October 30th 2023Pharmacy workers embark on a multiday strike; Fathers are taking paid family leave to bond with their newborns; the FDA is set to evaluate a pioneering gene therapy for sickle cell disease (SCD).
Read More
STELLAR, SOTERIA Data Provide Insight Into Effects of Sotatercept in Pulmonary Arterial Hypertension
October 28th 2023At ERS International Congress 2023, new data related to use of sotatercept offered providers additional insight into the effects of the agent in people with pulmonary arterial hypertension (PAH).
Read More
Updates in Federal Legislation Addressing Digital Therapeutics, Access to Care
October 28th 2023Although all legislation is currently on hold in Congress, there are important actions under consideration for pharmacy, including digital therapeutics, access to care, and health care disparities.
Read More
Study Identifies Core Instruments for Monitoring Physical Function in Hemophilia
October 28th 2023The study identified practical instruments for monitoring physical function in people with hemophilia by pinpointing 11 potential markers and establishing performance-based tests for 5 of these activities.
Read More
Ixazomib Shows Efficacy, Tolerability in Real-World R/R Multiple Myeloma Treatment
October 28th 2023A study of patients with relapsed or refractory (R/R) multiple myeloma who received ixazomib-based therapy in real-world settings found the treatment effective and tolerable in clinical practice.
Read More
Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features
October 27th 2023Patients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class exposure, experienced significant progression-free survival benefit with ciltacabtagene autoleucel.
Read More
Severe Influenza Strikes US Children and Adolescents in 2022-2023 Season
October 27th 2023The CDC found that the 2022-2023 influenza season had high severity among children and adolescents, resulting in them recommending that everyone receive the annual influenza vaccine by the end of October.
Read More
The number of suicides among US military members and their families slightly decreased in 2022; Democratic lawmakers proposed legislation that would require employers to provide paid time off following a pregnancy loss; Pfizer and BioNTech’s flu–COVID-19 vaccine generated a strong immune response against strains of the viruses in an early- to mid-stage trial.
Read More
ANNEXA-I: Andexanet Alfa Shows Efficacy, Safety for Factor Xa Reversal in Acute ICH
October 27th 2023The phase 4 ANNEXA-I trial was stopped early after showing superior hemostatic efficacy and the capability to limit potentially life-threatening intracerebral hemorrhage (ICH) compared with usual care in patients taking oral factor Xa (FXa) inhibitors.
Read More
Damoctocog Alfa Pegol Demonstrates Safety and Efficacy in Hemophilia A
October 26th 2023While clinical trials offer controlled data, real-world studies like HEM-POWR bridge gaps, confirming damoctocog alfa pegol’s effectiveness and tolerance, establishing it as a valuable hemophilia A treatment option.
Read More